Prime Nordic Portfolio - Movers & Shakers November 2019
Amongst those securities held within the Prime Nordic portfolio, the company is pleased to report that we have seen some significant and interesting developments within the following investments.
Kambi Group plc signs partnership with Seneca Gaming Corporation
Agreement includes provision of Kambi sportsbook to Seneca Resorts & Casinos’ three properties in New York, with online to follow pending regulation.
Kambi Group plc, the leading global sports betting supplier, has signed a long-term partnership agreement with Seneca Gaming Corporation (“SGC”), which operates three Class III gaming operations in Western New York, in collaboration with Bragg Gaming Group, a leading gaming and platform provider.
The multi-channel deal will see Kambi install its cutting-edge portfolio of on-property sports wagering products inside the three New York casinos operated by SGC; Seneca Niagara Resort & Casino in Niagara Falls, Seneca Buffalo Creek Casino in Buffalo, and Seneca Allegany Resort & Casino in Salamanca. Subject to regulatory approval, the deal will also see Bragg Gaming Group provide casino and player account management through its subsidiary ORYX.
Dominic Mansour, Bragg Gaming Group Chief Executive, said: “The agreement with Seneca and Kambi is a game-changer for Bragg. The US casino and sports betting market is rapidly expanding, and Bragg’s expertise in casino and player account management positions us well to take advantage of this growth. Entering the market with two such strong partners as Kambi and Seneca is an ideal scenario.”
Charles Wilken, the head of Investment Banking at Mangold Fondkommission AB just spent kr469k on shares.
Even if it's not a huge purchase, we think it was good to see that Charles Wilken, the Head of Investment Banking of Mangold recently shelled out kr469k to buy stock, at kr626 per share.
We take confidence from the longer term picture of such insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Mangold Fondkommission.
INVISIO Receives Follow-up Order for SEK 25 Million From its New Customer, the Belgian Army
In partnership with Thales Belgium INVISIO has received an expected follow-up order from the Belgian army for communication and hearing protection systems. The order value for INVISIO is SEK 25 million and deliveries are planned for the fourth quarter of 2019 and the first half of 2020.
In October 2019 INVISIO won the Belgian army's procurement contract for communication and hearing protection solutions. The program aims to protect soldiers' hearing while improving their communication capacity in critical environments.
The order received is the expected follow-up order announced earlier.
It was received in partnership with Thales Belgium, the main contractor for the program.
"Winning the Belgian army's contract in October is significant for INVISIO in that it is one of several indications that the defense and security industry is starting to increase its focus on the need for communication and hearing protection in critical environments. This expected follow-up order means that the partnership is developing according to plan", says Lars Højgård Hansen, CEO of INVISIO Communications.
On November 6, 2019, Fluicell AB launched Biopixlar®, a completely new concept in high-resolution bioprinting with roots in advanced microtechnology. Biopixels ® create three-dimensional complex biological tissue that has the potential to mimic tissues in human organs. These printed tissues can be used as models of patient tissue for drug development and research. According to the Board's assessment, the product has great commercial potential.
Biopixlar® is a brand new type of high-resolution bioprinter that can create detailed, multicellular and complex biological tissues. In addition to hardware and software development, Fluicell has discovered and patented molecular cell binders and methods that enable Biopixlar® to print cells directly in three dimensions with very high precision. More than just being a technological evolution, Biopixlar® is a fully integrated research platform loaded with new technology. Biopixlar® is controlled through a graphical, user-friendly interface to help researchers reach their goals - whether in drug development, regenerative medicine or transplant research.
For further information, please contact: